Sinuwave™ is a therapy under development for the treatment of chronic sinusitis, utilizing photodisinfection to destroy antibiotic resistant microbes in the inflamed sinus and thereby relieve symptoms of this debilitating disease. Sinuwave Technologies Corporation (www.sinuwave.com) is currently in the early stages of developing this product, and will rely heavily on the team at Ondine Biomedical Inc. throughout the process.
- Every year, Chronic Sinusitis patients make 15 million visits to outpatient clinics
- More than half of all Chronic Sinusitis outpatient visits result in prescription medication.
- Chronic Sinusitis patients visit their primary physicians twice as often as those without the disorder, and have 5 times as many prescriptions filled
- Chronic Sinusitis patients can spend up to 1/3 of the year on medication
The Sinuwave™ Advantage
It is estimated that 500,000 patients currently live with chronic sinusitis that is unresponsive to both surgical intervention and medical therapy, such as antibiotics. Photodisinfection is able to destroy inflammatory molecules and treat topical infections without generating resistance, suggesting that it will become a powerful tool in the treatment of chronic sinusitis.
Product Development Status
This product is in the early stages of development, including in vitro testing at Ondine Research Labs.